Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche Discontinues Genmab Antibody Project | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Roche Discontinues Genmab Antibody Project

Roche will discontinue development of Genmab's RG1507, an IFG-1R antibody.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche will discontinue development of RG1507, a monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R). The decision was due to the available clinical data, the large number of molecules targeting the same pathway that are presently in development and the prioritization of the Roche portfolio. The decision was not as a result of safety concerns.

RG1507 is a fully human antibody created by Genmab under a collaboration with Roche. RG1507 was in Phase II development for multiple indications including sarcoma and non small cell lung cancer.

“Despite this setback, Roche and Genmab continue to have a strong working relationship, with one shared aim of developing and providing novel efficacious agents to the patients that need them,” said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters